

NONDISCLOSURE AGREEMENT

THIS NONDISCLOSURE AGREEMENT (“Agreement”) is made as of the ____ day of May, 2014 (“Effective Date”) by and between Novarum Futuris, Inc., a Delaware corporation (“Company”), and the potential investor executing this Agreement (“Potential Investor”).

WHEREAS, for the purpose of assisting Potential Investor in determining whether to invest in Company, Potential Investor wishes to receive information that Company wants to keep confidential relating to Company’s business plan, financial matters, and products and/or services currently under development; and

WHEREAS, Company, in order to permit Potential Investor to make such a determination, wishes to disclose to Potential Investor to certain confidential information of Company.

NOW, THEREFORE, in consideration of the above recitals, the covenants hereinafter contained, and other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged) the undersigned hereby agree as follows:

1. **Potential Investor’s Obligations.** Potential Investor agrees for the Nondisclosure Period (defined below) (i) to hold all of the Confidential Information of Company in strict confidence, (ii) not to make use of any Confidential Information of Company in any manner other than for purposes of evaluating a potential investment in Company, including, but not limited to, not using any Confidential Information to design, develop or produce products or services, and (iii) not to copy the Confidential Information of Company, in each instance without the prior written consent of Company. As used in this Agreement, “Confidential Information” means and includes all information, whether verbal or written, disclosed by Company to Potential Investor and relating to Company’s business plans, strategies, financial information, research and development and marketing, including, without limitation, trade secrets, software, product design information, client, customer, vendor and potential investor lists, prices and pricing policies not otherwise published, research and development materials, prototypes, business plans, new products and services under development, and marketing, business and Internet strategies. Confidential Information does not include information which is (a) known by Potential Investor at the time of receipt from Company, (b) approved in writing for release from this provision by Company, (c) now or which hereafter becomes part of the public domain through no action or omission of Potential Investor, (d) independently developed by Potential Investor without the use of Confidential Information, and/or (e) acquired by Potential Investor from a third party without restriction on use or disclosure and without breach by such third party of an obligation of confidentiality. The “Nondisclosure Period” shall be begin on the Effective Date and continue for a period of five (5) years.
2. **For Investment Purposes Only.** Potential Investor acknowledges and agrees that this Agreement is made for the purposes of considering an investment in Company only and nothing herein shall be construed in any way as an offer, an attempted offer, or a solicitation for the sale of any product or service which has been or may be developed by Company.
3. **Actions Not Required.** Potential Investor understands that nothing herein (a) requires the disclosure of any Confidential Information of Company, which shall be disclosed, if at all, solely at the option of Company or (b) requires Company or Potential Investor to proceed with any proposed transaction or relationship in connection with which Confidential Information of Company may be disclosed.
4. **Property Rights.** Company retains all of its intellectual property rights in and to its Confidential Information. Immediately upon a written request by Company at any time, Potential Investor will turn over to Company all Confidential Information of Company and all documents or media containing any Confidential Information of Company and any and all copies or extracts thereof.
5. **No License Granted.** Neither the execution and delivery of this Agreement nor the furnishing of any Confidential Information of Company by Company shall be construed as granting to Potential Investor either expressly, by implication, estoppel or otherwise, any license under any invention, patent, trademark, or copyright now or hereafter owned or controlled by Company.

6. **No Adequate Remedy At Law.** Potential Investor acknowledges and agrees that due to the unique nature of the Confidential Information of Company, there can be no adequate remedy at law for any breach of its obligations hereunder, that any such breach may allow Potential Investor or third parties to unfairly compete with Company resulting in irreparable harm to Company, and, therefore, that upon any such breach or any threat thereof, Company shall be entitled to (a) specific performance and other injunctive relief without the necessity of posting a bond, in addition to whatever remedies it might have at law, and (b) be indemnified by Potential Investor from any loss or harm, including, without limitation, attorney's fees, in connection with any breach or enforcement of Potential Investor's obligations hereunder or the unauthorized use or release of any such Confidential Information of Company. Potential Investor shall notify Company in writing immediately upon the occurrence of any such unauthorized release or other breach of which it is aware.
7. **Governing Law.** This Agreement shall be governed in all respects by the laws of the State of Delaware without regard to the conflict of law provisions of such state. This Agreement shall be binding upon the successors and assigns of the respective parties.
8. **Disclosure Under Court Order.** Potential Investor may make disclosures required by court order if Potential Investor (a) uses reasonable efforts to limit disclosure and to obtain confidential treatment or a protective order and (b) promptly provides notice to Company of and allows Company to participate in the proceeding.
9. **Notice.** All notices or requests required or contemplated by this Agreement shall be in writing and (a) if from Company to Potential Investor, shall be hand-delivered or mailed to Potential Investor's address as set forth on the signature page hereto, or such other address as Potential Investor shall specify in written notice to Company, or (b) if from Potential Investor to Company, shall be hand-delivered or mailed to Company's address as set forth on the signature page hereto, or such other address as Company shall specify in written notice to Potential Investor. Requests or notices given by personal delivery shall be deemed given and received at the time of delivery and requests or notices given by mail shall be deemed given and received the earlier of three days from the date of mailing or upon receipt.
10. **General Provisions.** In the event that any of the provisions of this Agreement shall be held by a court or other tribunal of competent jurisdiction to be illegal, invalid or unenforceable, such provisions shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect. This Agreement supersedes all prior discussions and writings and constitutes the entire agreement between the parties with respect to the subject matter hereof. This Agreement may not be modified or amended except by an instrument in writing signed by the parties hereto. Accordingly, no course of conduct shall constitute an amendment or modification of this Agreement. No waiver of this Agreement will be binding upon either party unless made in writing and signed by a duly authorized representative of each party and no failure or delay in enforcing any right will be deemed a waiver. All waivers shall be strictly construed.

IN WITNESS WHEREOF, the parties hereto have duly executed and have caused this Agreement duly to be executed and delivered as of the Effective Date.

POTENTIAL INVESTOR:

Print name of Potential Investor

Signature

Representative capacity, if any

Address

Email and/or Fax Number

COMPANY:

NOVARUM FUTURIS, INC.

By: _____
Natasha Walstra, President

1679 S. Dupont Hwy, Suite 100
Dover, Delaware 19901

Please fax into (888) 391-0457 or email to legal@novarumfuturis.com

NOVARUM FUTURIS, INC.
(a Delaware corporation)

Reservation Agreement

To: Novarum Futuris, Inc.
Attn: Corporate Secretary

Ladies and Gentlemen:

Section 1

1. **Background.** The undersigned (the “*Investor*”) desires to reserve shares (the “*Shares*”) of the Common Stock, par value \$0.001 per share (the “*Common Stock*”), of Novarum Futuris, Inc., a Delaware corporation (the “*Company*”), which are being offered for subscription pursuant to a separate Subscription and Investment Representation Agreement.

2. **Reservation of Shares.**

(a) The Investor hereby reserves that number of Shares of Common Stock as set forth on the signature page hereto (the “*Reserved Shares*”), at a reservation price per Share of \$1.00, for a total reservation price as set forth on the signature page hereto (the “*Reservation Price*”). The Reservation Price may be paid to the Company by any of the payment methods set forth on **Exhibit A**, and an executed original counterpart of the signature page to this Reservation Agreement shall be sent to the Company at the address set forth on **Exhibit A**, in each case on or before June 30, 2014, after which no further reservation of Shares will be accepted.

(b) If the Investor subscribes for the Reserved Shares on or before July 15, 2014, the Reservation Price shall be applied to the purchase price for said Shares. If the Investor does not subscribe for the Reserved Shares by such date for any reason, or requests to release their reserved shares, or if the Company rejects the Investor’s subscription for said Shares, the Reservation Price shall be refunded to the Investor in full with 7-10 business days after such an event occurs.

3. **Counterparts.** This Agreement may be executed through the use of separate signature pages or in any number of counterparts (including facsimile counterparts), and each of such counterparts shall, for all purposes, constitute one and the same agreement binding on all of the parties thereto, notwithstanding that all parties are not signatories to the same counterpart.

* * * * *

Investor's Signature Page

The amount of the Reservation Price and the number of whole shares of Common Stock reserved by the Investor are as follows:

\$ _____	_____
Reservation Price	Number of whole shares of Common Stock Reserved
[Min. \$250]	[Min. 250 shares]

Dated: _____, 2014

Name of Investor (typed or printed)

Street Address

Signature of Investor or Officer

City, State and ZIP Code

Name and Title
(If signing on behalf of an entity)

Telephone Number: _____

E-Mail Address: _____

EXHIBIT A

Address and Payment Information

The executed counterpart of the signature page to this Reservation Agreement shall be emailed or faxed to:

Novarum Futuris, Inc.
Attn: Corporate Secretary
1679 S. Dupont Hwy, Suite 100
Dover, Delaware 19901
Fax: 1-888-871-2656
Email: legal@novarumfuturis.com

Payment of the Reservation Price may be made by any of the following methods:

1. By wire transfer to:

Bank: Bank of America
ABA #: 026009593
Account #: 002260008484 (Business Checking)
Account Name: Novarum Futuris, INC

2. Via the payment options at the website www.nfreserve.com

If any questions regarding payment please call (888) 391-0457. Once we receive the executed NDA, Reserve Form, and Completion of Reserve Payment you will receive within 3 business days the following.

1. Business Prospectus
2. Shareholders Agreement
3. Company Bylaws
4. Subscription Agreement
5. Invitation to our upcoming forums
6. Invitation to our upcoming funding event